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Abstract. Working under the assumption that up- or down-
regulation of genes implicated in chemoresistance may be the
result of altered function of regulatory transcription factors
(TF), over-represented TF-binding sites of gene lists previously
associated with doxorubicin resistance were the target of our
search. First, a data warehouse was set up containing 52 genes
which were present in at least two gene lists; of those, proximal
promoter sequences (1 kb upstream and 0.05 kb downstream
of the transcriptional start sites) could be retrieved from
genomic databases for 45 genes using the EZ-Retrieve. The
TOUCAN tool MotifScanner, which searches the TRANSFAC
database, was used to detect TF-binding sites (TFBSs) in our
set of sequences. The statistics tool of the Java program
TOUCAN was applied to the data with the appropriate
expected frequencies file to compare the measured prevalence
to a background model. The most significantly over-
represented TFBS was that of E47 (p=0.00024, prevalence: 0.2
vs. background: 8.19E-6). In summary, based on the results of
our analysis it is hypothesized that the E47 transcription factor
may contribute to doxorubicin resistance. 
The anthracycline antibiotic doxorubicin (Adriamycin) is
widely used for the treatment of lung, breast, ovarian and
gastric cancer, lymphomas and leukemias. Although a
number of different mechanisms have been proposed for
the cytotoxic effect of anthracyclines, the primary
mechanism of its action is likely to be the inhibition of
DNA biosynthesis via binding to topoisomerase II,
consequently conferring S/G2 cell cycle arrest (1-3). The
major cause of failure of successful cancer treatment is
primary drug resistance or the development of secondary
antineoplastic drug resistance. Many different mechanisms
of resistance to chemotherapy have been identified, which
may act simultaneously, be interconnected and mutually
influence each other.
Several studies demonstrated that gene expression
profiles of cancer cell lines (4, 5) and primary neoplasms
(6, 7) could predict the response to a defined anticancer
drug treatment regime. DNA array technology for mRNA
expression profiling may provide information about the
drug resistance status of a given patient and, thus, offer a
chance for individual patient-tailored chemotherapy
regimens in the future. For example, van't Veer et al.
demonstrated that breast cancer prognosis can be deduced
from the gene expression profile of primary tumors (8) and
Chang et al. demonstrated that the gene expression profiles
of primary breast cancer could predict the response to
docetaxel (9). 
The fact that more than 5% of human genes are predicted
to encode transcription factors (TF) underscores their
importance in cell physiology (10). Transcriptional
regulatory regions, the so-called promoter sequences,
located before the start codon of each gene, contain short –
usually 4 to 10 bases long – TF-binding sites (TFBSs). Once
activated, TFs bind to the TFBS and, through interactions
with other components of the transcription machinery,
promote access to DNA and facilitate the recruitment of the
RNA polymerase enzymes to the transcription start site (11).
One TF may bind to the promoters of several genes and the
promoter region of one gene may contain several TFBSs
(12). The involvement of different kinds of TFs in the
regulation of a given gene makes possible the integration of
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several signaling pathways; this is called ‘combinatorial
transcription regulation’ (13).
A major new challenge in genomic research is to
understand and decipher the mechanisms that regulate the
expression of co-regulated gene sets in microarray
experiments. An important step in this process is the ability
to identify regulatory elements, notably the binding sites in
DNA for transcription factors. In our study, we aimed to
perform an in silico analysis to detect the prevalence of
over-represented TFBSs in promoter regions of published
gene lists associated with doxorubicin resistance. 
Materials and Methods
Source data collection. Our previously published gene lists were re-
analyzed and the PubMed (http://www.pubmed.com/) was searched
for papers presenting additional gene lists associated with
doxorubicin resistance in cell lines using the key words
“doxorubicin”, “cancer”, “gene expression” and “microarray”.
Those publications where the results were limited to a specific cell
line were excluded, as these resistance models could describe cell
line-specific resistance mechanisms. To reduce heterogeneity,
publications where clinical samples or treatment reponses were
investigated were also excluded. All together, three different recent
studies (see below) describing gene lists associated with
doxorubicin resistance, using different microarray platforms, were
analyzed.
In our recent work, the expression profiles of 13 different
human tumor cell lines of gastric (EPG85-257), pancreatic (EPP85-
181), colon (HT29) and breast (MDA-MB-231) origin and their
counterparts resistant to daunorubicin or doxorubicin were
contrasted (16). cDNA arrays spotted at Stanford University
containing 43,000 cDNA clones (~30,000 unique genes) were
interrogated and the top 79 genes best correlated with doxorubicin
resistance were identified.
Kang et al. performed global gene expression analysis using
Affymetrix HG-U133A microarrays and identified differentially-
expressed genes associated with the acquisition of chemoresistance
to the commonly used drugs 5-fluorouracil, doxorubicin and
cisplatin in human gastric cancer of different cell lines (17). The
gene expression patterns of ten chemoresistant gastric cancer cell
lines were compared with those of four parent cell lines using fold-
change and the Wilcoxon's test for data analysis. These authors
identified 74 genes differentially expressed in doxorubicin-resistant
gastric cancer cell lines
In another study, 30 cancer cell lines were tested for sensitivity
to 5-fluorouracil, cisplatin, cyclophosphamide, doxorubicin,
etoposide, methotrexate, mitomycin C, mitoxantrone, paclitaxel,
topotecan and vinblastine at drug concentrations that can be
systemically achieved in patients (18). First, using a resistance
index, the cell lines were designated as sensitive or resistant, then
the subset of resistant versus sensitive cell lines for each drug was
compared. Gene expression signatures for all cell lines were
obtained by searching Affymetrix U133A arrays. An individual
prediction profile for the resistance to each chemotherapy agent
was constructed containing 253 genes associated with doxorubicin
resistance. The overall accuracy of the predictions in a leave-one-
out cross validation was 86%. 
Sequence extraction. First, proximal promoter sequences (1 kb
upstream and 0.05 kb downstream of the transcriptional start sites)
were extracted from genomic databases using EZ-Retrieve (19).
EZ-Retrieve uses the NCBI UniGene and LocusLink (20),
TRANSFAC and TFSEARCH (21) databases. The extracted
sequences were saved in FASTA format and then imported into
TOUCAN (the sequence file is available on request from the
corresponing author).
TFBS identification. The Java program TOUCAN was used for
comparative promoter analyses of the selected genes (22).
Transcription factors not only bind unique DNA sequences, but
also have a degree of non-specificity in their sequence recognition.
Thus, whether a TFBS exists in a promoter sequence cannot simply
be determined by searching for an exactly matching sequence.
Instead, matrices are used that give the different nucleotides
various weightings depending on their importance for TF binding.
A collection of these matrices exists in the TRANSFAC database
(www.gene-regulation.com/pub/databases.html#transfac). The
relative occurrences in the list of differentially-regulated genes of a
set of TFs (TRANSFAC matrices) have to be compared. 
The TOUCAN tool MotifScanner, which searches the
TRANSFAC database (23), was used to detect TFBSs in our sets
of sequences. The prior (stringency level) was set to 0.1 and the
human promoter set of the Eukaryotic Promoter Database (EPD)
was chosen as third-order background model. The statistics tool
of TOUCAN was applied to the data produced by MotifScanner in
combination with the appropriate expected frequencies file
(human EPD), thereby detecting over-represented features
(showing positive significance values) in the sets of selected genes.
Finally, the Bonferroni-correction was subsequently applied to
compensate for the effect of multiple testing (Table I). 
Results
For the comparative promoter analysis the three different
gene lists were combined. Out of the total of 312 individual
genes, 52 were repeatedly associated with doxorubicin
resistance (see Table II). To increase the accuracy of our
model, other genes were dismissed and our attention
focused solely on the repeated genes. Then, out of the 52
repeated genes, promoter sequences for 45 genes were
retrieved (see Figure 1).
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Table I. Over-represented transcription factor (TF)-binding sites before
and after Bonferroni-correction.
TF n p value Significant after 
Bonferroni
E47 9 0.00024 Yes
TAL1alphaE47 6 0.01 No
EGR3 4 0.02 No
NFY 17 0.03 No
HEN1 4 0.03 No
ISRE 9 0.05 No
The comparative promoter analysis revealed the E47
transcription-factor as being over-represented in our gene set
(p=0.00024, n=9, prior frequency: 8.19E-6). These TFBSs
were distributed on eight different genes, of which the SKP2
gene had two E47 TFBSs. The consensus sequence for E47
TFBS is: RCAGNTG (TRANSFAC accession no: R02139).
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Table II. Genes associated with doxorubicin resistance in at least two different published gene lists.
UniGene ID Affy ID Public ID Symbol Gene title
Hs.102267 204298_s_at NM_002317 LOX lysyl oxidase
Hs.125457 221531_at AF309553 REC14 recombination protein REC14
Hs.126256 205067_at NM_000576 IL1B interleukin 1, beta
Hs.130865 214247_s_at AU148057 DKK3 dickkopf homolog 3
Hs.133892 206116_s_at NM_000366 TPM1 tropomyosin 1 (alpha)
Hs.153355 212636_at AL031781 QKI quaking homolog, KH domain RNA binding
Hs.155223 203439_s_at BC000658 STC2 stanniocalcin 2
Hs.156346 201292_at AL561834 TOP2A topoisomerase (DNA) II alpha 170 kDa
Hs.1594 204962_s_at NM_001809 CENPA centromere protein A, 17 kDa
Hs.171466 219518_s_at NM_025165 ELL3 elongation factor RNA polymerase II-like 3
Hs.1908 201859_at NM_002727 PRG1 proteoglycan 1, secretory granule
Hs.191583 213599_at BE045993 OIP5 Opa-interacting protein 5
Hs.199695 212281_s_at BF038366 MAC30 hypothetical protein MAC30
Hs.23348 210567_s_at BC001441 SKP2 S-phase kinase-associated protein 2 (p45)
Hs.24529 205393_s_at NM_001274 CHEK1 CHK1 checkpoint homolog
Hs.250687 205803_s_at NM_003304 TRPC1 transient receptor potential cation channel, subfamily C, member 1
Hs.257049 204236_at NM_002017 FLI1 friend leukemia virus integration 1
Hs.259047 203434_s_at NM_007287 MME membrane metallo-endopeptidase (CALLA, CD10)
Hs.26471 212745_s_at AI813772 BBS4 Bardet-Biedl syndrome 4
Hs.279766 218355_at AF179308 KIF4A kinesin family member 4A
Hs.279905 219978_s_at NM_018454 NUSAP1 nucleolar and spindle associated protein 1
Hs.309674 212473_s_at BE965029 MICAL2 flavoprotein oxidoreductase MICAL2
Hs.311589 205006_s_at NM_004808 NMT2 N-myristoyltransferase 2
Hs.312102 208951_at BC002515 ALDH7A1 aldehyde dehydrogenase 7 family, member A1
Hs.315167 219000_s_at NM_024094 DCC1 defective in sister chromatid cohesion homolog 1
Hs.324470 205882_x_at NM_016824 ADD3 adducin 3 (gamma)
Hs.334562 203213_at AL524035 CDC2 cell division cycle 2, G1 to S and G2 to M
Hs.334828 213008_at BG403615 FLJ10719 hypothetical protein FLJ10719
Hs.344037 218009_s_at NM_003981 PRC1 protein regulator of cytokinesis 1
Hs.36708 203755_at NM_001211 BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta
Hs.388160 209512_at BC004331 C9orf99 chromosome 9 open reading frame 99
Hs.395771 201432_at NM_001752 CAT catalase
Hs.414795 202628_s_at NM_000602 SERPINE1 serine proteinase inhibitor, clade E, member 1
Hs.418138 212464_s_at X02761 FN1 fibronectin 1
Hs.42650 204026_s_at NM_007057 ZWINT ZW10 interactor
Hs.434953 208808_s_at BC000903 HMGB2 high-mobility group box 2
Hs.435795 201163_s_at NM_001553 IGFBP7 insulin-like growth factor binding protein 7
Hs.438231 209277_at AL574096 TFPI2 tissue factor pathway inhibitor 2
Hs.446406 216870_x_at AF264787 DLEU2 deleted in lymphocytic leukemia, 2
Hs.489033 209993_at AA455911 ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1
Hs.528669 218662_s_at NM_022346 HCAP-G chromosome condensation protein G
Hs.624 202859_x_at NM_000584 IL8 interleukin 8
Hs.6385 53991_at AA127623 KIAA1277 KIAA1277
Hs.72550 207165_at NM_012485 HMMR hyaluronan-mediated motility receptor 
Hs.75277 212479_s_at AK022815 FLJ13910 hypothetical protein FLJ13910
Hs.77274 205479_s_at NM_002658 PLAU plasminogen activator, urokinase
Hs.79078 203362_s_at NM_002358 MAD2L1 MAD2 mitotic arrest deficient-like 1
Hs.799 203821_at NM_001945 DTR diphtheria toxin receptor
Hs.81892 202503_s_at NM_014736 KIAA0101 KIAA0101
Hs.89497 203276_at NM_005573 LMNB1 lamin B1
Hs.89714 214974_x_at AK026546 CXCL5 chemokine (C-X-C motif) ligand 5
Hs.93121 205240_at NM_013296 GPSM2 G-protein signalling modulator 2
Discussion
In eukaryotes, protein synthesis is regulated at many levels
during the transcription from DNA to the mature protein.
The first and most important step is the transcriptional
initiation, since none of the other steps is possible if no
primary RNA transcript is formed. Given a set of genes that
share a similar expression profile, a logical step in the analysis
is to search for the mechanism that explains their co-
expression. The basic assumption is that genes that show a
similar expression profile in an experiment might be regulated
by the same transcriptional regulators. The activities of many
TFs are context-dependent and can be modulated by other
modulators nearby. Thus, a single TF can induce the
transcription of specific genes while repressing others.
An important step in the identification of relevant TFs in
this process is the ability to identify regulatory elements,
notably the binding sites in DNA for TFs. First, a co-
regulated set of genes is identified, then for each gene in the
selected set the promoter or upstream region is identified.
Finally, statistically over-represented motifs are retrieved
from this set of sequences as potential TFBSs. This
approach targets the difficult problem of what to do when
little information is available regarding the regulatory
system and sequence recognition by the protein. 
In our study, the over-representation of the binding site
of the E47 TF was identified in the promoter regions of
genes associated with doxorubicin resistance. The E47
(accession number: T00207, also called TCF3, BCF-1;
E2A.E47; E2A-E47; IEBP1 (rat); and E2A) belongs to the
basic helix-loop-helix factors (HLH) class of TFs, to the
family of ubiquitous (class A) factors. The E47 contains two
trans-activation domains (24), a leucine repeat, a basic
region and the helix-loop-helix domain. The basic region
contacts the DNA, and the HLH domain is the dimerization
interface (25). The dimerization is a prerequisite for DNA-
binding. Upon dimerization, the alpha-helical content may
significantly increase supporting the four-helix bundle
dimerization interface. Upon DNA-binding of the dimer,
the basic regions adopt alpha-helical conformation as well.
Id helix-loop-helix proteins function as regulators of cell
growth and differentiation and, when overexpressed, can
induce malignant transformation. Enforced, ectopic
expression of the E47 basic HLH (bHLH) protein in human
adenocarcinoma cell lines efficiently sequestered
endogenous Id proteins as Id-bHLH heterodimers, leading
to growth arrest of the cells. E47 plays an active role in
tumor cell growth by promoting angiogenesis (26). As the
E47 proteins establish a direct transcriptional link between
a cell cycle inhibitor, p21(Cip1) and a neutrophic receptor,
TrkB, these proteins would play an important role in co-
ordinating key events of cell cycle arrest (27). Enforced
overexpression of a mutant E47 protein, deficient in
transactivation and DNA-binding function, also partially
inhibited cell growth. Deregulated expression of Id proteins
contributed to the uncontrolled proliferation of tumor cells
in colorectal cancer (28). Interestingly, these tumor
suppressor properties (29) are more specific for tumor
proliferation, not for resistance. 
The E47 also interacts with other transcription factors, such
as the E12 (Accession no: T00204), Id2 (T01212), Myf-4
(T00520), Myf-5 (T00521), Myf-6 (T00522), MyoD (T00525),
Tal-1 (T00790), Tal-1beta (T01448) and Tal-2 (T01630). The
E47 is part of the MEF-1 complex; it induces hyper-
phosphorylation of MyoD upon association. Additionally, E47
induces transcription of IgH, but also of the IgH-stimulating
Oct-2 gene and the recombination-activating genes RAG-1 and
-2, thus stimulating IgH rearrangement as well (30). Although a
promoter polymorphism in the MHC gene influences the
binding of the E47 TF (31), no similar phenomenon has been
described in association with drug resistance.
Other transcription factors, e.g., NF-κB and E2F, have
already been associated with doxorubicin resistance. The
use of agents that block NF-κB function has been highly
beneficial in the treatment of tumors in combination with
standard anticancer therapies (32). Treatment with BAY 
11-7082, an irreversible inhibitor of NF-κB-phosphorylation,
induced a higher percentage of apoptosis in vincristine- and
doxorubicin-resistant cell lines. The suppression of
constitutive NF-κB activity by BAY 11-7082 may be a useful
treatment for MDR leukemias (33). The targets of
doxorubicin, the topoisomerase II proteins, are direct
targets of the E2F TF-mediated transcription and E2F has
been proposed to be involved in drug resistance (34). 
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Figure 1. Overview of the data input and the performed statistical analysis.
However, no over-representation for these TFBSs was
detected in our study. The question arises of whether a
change in the level of transcription of a specific gene is
caused by the TF acting directly at the promoter of the gene
or through regulation of other transcription factors working
at the promoter. It is apparent that these kinds of models
are highly complex and difficult to set up. Therefore, the
results of this in silico analysis will need to be coupled with
biological experiments.
Gene regulatory sequences hold the key to understanding
how genes are regulated by programmed and environmental
signals. Technologies that permit global transcription
profiling force the researcher to take a holistic view and
consider biological pathways and processes that would
otherwise be ignored. The hypothesis that we have proposed
should not be considered to be a model that can explain all
possible mechanisms of doxorubicin resistance, but must be
considered as just one of several influences. 
However, our computational approach does not provide
information about the functional impact of the identified TFs
on gene activation. For the investigation of the TF-DNA
complex interaction, experiments should be carried out using
functional assays, such as the electrophoretic mobility shift
assay (EMSA) or chromatin immunoprecipitation (ChIP).
EMSA is based on the observation that protein:DNA
complexes migrate more slowly than free DNA molecules
when subjected to non-denaturing polyacrylamide or agarose
gel electrophoresis; hence sequence-specific interactions may
be investigated. The principle of the ChIP assay is that DNA-
bound proteins (including TFs) in living cells can be cross-
linked to chromatin by a gentle formaldehyde fixation. Once
the proteins are immobilized on the chromatin, the whole
protein-DNA complex can be immunoprecipitated using an
antibody against the protein in question. The isolated
protein/DNA fraction can then be purified for DNA. The
identity of the DNA fragments isolated in connection with the
protein can then be determined by PCR. Once we have
experimental data confirming the binding of the E47 TF,
further functional studies can be performed. These include
RNA interference and stable transfection to modulate the
gene expression and sequencing to identify mutations and
SNPs in the E47 gene and in the E47 TFBS.
Conclusion
In summary, based on the results of our computer-simulated
analysis of the promoter regions of genes with altered gene
expression, we hypothesize that the E47 transcription factor
may contribute to doxorubicin resistance in cancer. These
results shed a new light on E47, as to date it was only
considered to be involved in cell proliferation. Thus, E47
might present a target for effective intervention against
doxorubicin resistance.
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